Statute Details
- Title: Healthcare Services (Exemption for Influenza Vaccination at Approved Retail Pharmacies) Order 2024
- Act Code: HSA2020-S752-2024
- Legislative Type: Subsidiary Legislation (SL)
- Authorising Act: Healthcare Services Act 2020
- Enacting Authority: Minister for Health (pursuant to section 53 of the Healthcare Services Act 2020)
- Order Number: S 752/2024
- Commencement: 1 October 2024
- Status: Current version as at 27 March 2026
- Key Provisions: Section 1 (citation and commencement); Section 2 (definitions); Section 3 (exemption for influenza vaccination at approved retail pharmacies)
- Core Exemptions in Section 3: Exemption from section 8 of the Healthcare Services Act 2020; partial exemption from section 31(1) (advertising restrictions)
- Operational Context: Applies only when influenza vaccination is administered at an “approved retail pharmacy” under a “sandbox trial” with specified conditions
What Is This Legislation About?
The Healthcare Services (Exemption for Influenza Vaccination at Approved Retail Pharmacies) Order 2024 (“the Order”) is a targeted regulatory instrument that enables influenza vaccinations to be administered in certain retail pharmacy settings in Singapore, without triggering specific prohibitions or restrictions that would otherwise apply under the Healthcare Services Act 2020 (“HSA”). In plain terms, it creates a controlled “trial” pathway for approved retail pharmacies to provide influenza vaccination services, while carving out limited legal exemptions for the pharmacy licence holder and related parties.
The Order is designed to support feasibility and safety testing. It does not broadly legalise influenza vaccination in all retail pharmacies. Instead, it is conditional: the vaccination must occur at an “approved retail pharmacy” and must be carried out by an “approved pharmacist” employed by the pharmacy licence holder, and it must be done in accordance with the conditions specified in the relevant regulatory schedule. This makes the Order a compliance-management tool—allowing innovation and service expansion while maintaining legal guardrails.
Practically, the Order also addresses advertising. Under the HSA, there are restrictions on advertising healthcare services. The Order provides a limited exemption so that a pharmacy licence holder (and a person acting on its authority) may advertise information relating to the administration of influenza vaccines at the approved retail pharmacy, but only within the scope of the sandbox trial and the relevant conditions.
What Are the Key Provisions?
Section 1: Citation and commencement confirms that the Order is the “Healthcare Services (Exemption for Influenza Vaccination at Approved Retail Pharmacies) Order 2024” and that it comes into operation on 1 October 2024. For practitioners, commencement is crucial because exemptions under subsidiary legislation typically only apply from the effective date.
Section 2: Definitions sets the interpretive framework. The Order relies heavily on definitions from other regulations, particularly the Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016). Specifically, it defines:
- “approved pharmacist” and “approved retail pharmacy” by reference to Part 2 of the Third Schedule to the 2016 Regulations;
- “holder of a pharmacy licence” as the person holding a pharmacy licence in respect of an approved retail pharmacy;
- “pharmacy licence” by reference to regulation 2(1) of the 2016 Regulations;
- “sandbox trial” as a trial conducted by the Ministry of Health under a set of terms and conditions issued by the Ministry to a holder of a pharmacy licence to test feasibility and safety of administration of influenza vaccines by approved pharmacists.
This cross-referencing approach is important for legal compliance. It means that the scope of who may vaccinate—and where—depends on the regulatory status conferred under the 2016 Regulations and the specific terms issued by the Ministry of Health for the sandbox trial.
Section 3: Exemption in relation to administration of influenza vaccine at approved retail pharmacy is the operative provision. It contains three main elements: (1) the conditions for applicability; (2) the exemption from section 8 of the HSA; and (3) the exemption from section 31(1) of the HSA (advertising restrictions).
Section 3(1): When the Order applies—the “sandbox trial” gatekeeping mechanism. The Order applies only where an influenza vaccine is administered at an approved retail pharmacy under a sandbox trial and the administration is:
- By an approved pharmacist who is employed by the holder of the pharmacy licence issued in respect of the approved retail pharmacy; and
- In accordance with the conditions specified in the third column of item 4 of Part 1 of the Third Schedule to the 2016 Regulations.
For practitioners, this is the compliance “checklist.” If any element is missing—e.g., the pharmacist is not an “approved pharmacist,” the pharmacist is not employed by the licence holder, the setting is not an “approved retail pharmacy,” or the administration does not comply with the specified conditions—then the exemptions in the Order may not apply.
Section 3(2): Exemption from section 8 of the HSA. The Order provides that section 8 of the Act does not apply to the holder of a pharmacy licence issued in respect of an approved retail pharmacy in relation to the administration of an influenza vaccine at the approved retail pharmacy.
While the extract does not reproduce the text of section 8, the legal effect is clear: the holder is relieved from whatever requirement or prohibition section 8 imposes, but only in the narrow context of influenza vaccination administered at the approved retail pharmacy under the sandbox trial framework. This is a classic “contextual exemption” drafting technique—limiting the exemption to the precise activity and setting.
Section 3(3): Exemption from section 31(1) of the HSA (advertising). The Order also states that section 31(1) of the Act does not apply to:
- (a) a holder of a pharmacy licence who advertises (or causes to be advertised) information relating to the administration of an influenza vaccine at the approved retail pharmacy to which the pharmacy licence relates; and
- (b) a person who, acting on the authority of a holder of a pharmacy licence, advertises (or causes to be advertised) such information.
This provision is particularly important for commercial operations. Retail pharmacies typically market services to the public. Without an exemption, advertising restrictions could create a compliance risk for both the licence holder and third-party marketing providers. The Order permits advertising of relevant information, but again within the scope of the approved retail pharmacy and the influenza vaccination activity contemplated by the sandbox trial.
Made on 27 September 2024 and signed by the Permanent Secretary (Policy and Development), Ministry of Health, the Order’s formalities confirm its validity and the date it was executed.
How Is This Legislation Structured?
The Order is concise and structured into three sections:
- Section 1 (Citation and commencement): identifies the instrument and its effective date (1 October 2024).
- Section 2 (Definitions): defines key terms, largely by reference to the Health Products (Therapeutic Products) Regulations 2016 and by describing the “sandbox trial” framework.
- Section 3 (Exemption): sets out the conditions under which the exemptions apply and specifies the HSA provisions that are disapplied (section 8 and section 31(1)), including the scope of permitted advertising.
Notably, the Order does not create a standalone regulatory scheme for vaccination. Instead, it functions as a targeted exemption overlay on top of the HSA and the 2016 Regulations. This means practitioners must read the Order together with the referenced schedules and the Ministry of Health’s sandbox trial terms.
Who Does This Legislation Apply To?
The Order applies to holders of pharmacy licences issued in respect of an approved retail pharmacy, but only when the pharmacy is participating in a sandbox trial for influenza vaccination. The exemptions are not general; they are tied to the specific activity of administering influenza vaccines at the approved retail pharmacy under the trial conditions.
It also affects approved pharmacists indirectly, because the administration must be carried out by an approved pharmacist employed by the licence holder. Additionally, it extends to advertisers and marketing actors who act on the authority of the licence holder, allowing them to advertise information relating to influenza vaccine administration at the approved retail pharmacy.
Why Is This Legislation Important?
This Order is significant because it demonstrates how Singapore manages the expansion of healthcare services through controlled exemptions rather than immediate broad deregulation. By limiting the exemption to sandbox trials and to approved retail pharmacies, the regulatory framework seeks to balance public health objectives (feasibility and safety) with operational flexibility for retail pharmacy providers.
From an enforcement and compliance perspective, the Order reduces legal uncertainty for pharmacy licence holders participating in the trial. Specifically, it disapplies section 8 of the HSA in relation to influenza vaccine administration at the approved retail pharmacy, and it disapplies section 31(1) to permit advertising of relevant information. This is likely to be critical for trial uptake, public awareness, and commercial viability.
For practitioners advising pharmacy operators, the key practical takeaway is that compliance must be activity-specific and condition-specific. The exemptions depend on meeting the defined criteria: approved retail pharmacy status, approved pharmacist employment, sandbox trial participation, and adherence to the conditions in the referenced schedule. Any deviation could jeopardise reliance on the exemption and expose the operator to the underlying HSA restrictions.
Related Legislation
- Healthcare Services Act 2020 (notably sections 8 and 31(1), which are disapplied in the Order)
- Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016), including:
- Third Schedule, Part 2 (definitions of “approved pharmacist” and “approved retail pharmacy”)
- Third Schedule, Part 1, item 4 (conditions for administration referenced in Section 3(1)(b))
Source Documents
This article provides an overview of the Healthcare Services (Exemption for Influenza Vaccination at Approved Retail Pharmacies) Order 2024 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.